TY - JOUR T1 - Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation JF - CMAJ Open SP - E653 LP - E661 DO - 10.9778/cmajo.20170042 VL - 5 IS - 3 AU - Jean-Eric Tarride AU - Lisa Dolovich AU - Gordon Blackhouse AU - Jason Robert Guertin AU - Natasha Burke AU - Veena Manja AU - Alex Grinvalds AU - Ting Lim AU - Jeff S. Healey AU - Roopinder K. Sandhu Y1 - 2017/08/22 UR - http://www.cmajopen.ca/content/5/3/E653.abstract N2 - Background: Screening for undiagnosed atrial fibrillation may lead to treatment with oral anticoagulation therapy, which can decrease the risk of ischemic stroke. The objective of this study was to conduct an economic evaluation of the Program for the Identification of 'Actionable' Atrial Fibrillation in the Pharmacy Setting (PIAAF-Pharmacy), which screened 1145 participants aged 65 years or more at 30 community pharmacies in Ontario and Alberta between October 2014 and April 2015.Methods: We used a 2-part decision model to evaluate the short- and long-term costs and quality-adjusted life-years (QALYs) of a pharmacy screening program for atrial fibrillation compared to no screening. Data from the PIAAF-Pharmacy study were used for the short-term model, and the relevant literature was used to extrapolate the benefits of the PIAAF-Pharmacy study in the long-term model. Costs and QALYs were calculated from a payer perspective over a lifetime horizon and were discounted at 1.5%/year.Results: Screening for atrial fibrillation in pharmacies was associated with higher costs ($26) and more QALYs (0.0035) compared to no screening, yielding an incremental cost per QALY gained of $7480. Univariate and probabilistic sensitivity analyses confirmed that screening for atrial fibrillation in a pharmacy setting was a cost-effective strategy.Interpretation: Our results support screening for atrial fibrillation in Canadian pharmacies. Given this finding, efforts should be made by provincial governments and pharmacies to implement such programs in Canada. The addition of atrial fibrillation screening alongside screening and management of other cardiovascular conditions may help to reduce the burden of stroke. ER -